Cargando…

Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). To characterise the relative safety profile of tofacitinib to biologic disease-modifying antirheumatic drugs (bDMARDs), the accrued patient-years (pt-yrs) of exposure needed in an RA clinical trial programm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Curtis, Jeffrey R., Zhang, Richard, Krishnaswami, Sriram, Anisfeld, Andrew, Chen, Yan, Strengholt, Sander, Chen, Connie, Geier, Jamie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2016
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323490/ https://www.ncbi.nlm.nih.gov/pubmed/27470086 http://dx.doi.org/10.1007/s10067-016-3359-x

Ejemplares similares

Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis
por: van Vollenhoven, Ronald, et al.
Publicado: (2019)

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2014)

Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
por: Strand, Vibeke, et al.
Publicado: (2017)

Model‐Based Comparison of Dose‐Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients
por: Suzuki, Misaki, et al.
Publicado: (2019)

Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
por: Clowse, Megan E. B., et al.
Publicado: (2016)

Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
por: Strand, Vibeke, et al.
Publicado: (2015)

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
por: Fleischmann, Roy, et al.
Publicado: (2016)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
por: Curtis, Jeffrey R, et al.
Publicado: (2016)

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
por: Wollenhaupt, Jürgen, et al.
Publicado: (2019)

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
por: Mariette, Xavier, et al.
Publicado: (2018)

Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2018)

Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials
por: Landewé, Robert B. M., et al.
Publicado: (2016)

Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
por: Isaacs, John D, et al.
Publicado: (2014)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
por: Li, Zhan-Guo, et al.
Publicado: (2018)

Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp—A Usability Study
por: Sciascia, Savino, et al.
Publicado: (2020)

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
por: Strand, Vibeke, et al.
Publicado: (2016)

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
por: Cohen, Stanley B, et al.
Publicado: (2017)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment
por: Winthrop, Kevin L., et al.
Publicado: (2021)

Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2017)

Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis
por: Kim, Joon Wan, et al.
Publicado: (2013)

Fracture in clinical studies of tofacitinib in rheumatoid arthritis
por: Hansen, Karen E., et al.
Publicado: (2022)

An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective
por: Claxton, Lindsay, et al.
Publicado: (2018)

Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib
por: Inanc, Nevsun, et al.
Publicado: (2023)

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
por: Cohen, Stanley B, et al.
Publicado: (2020)

Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India
por: Phatak, Sanat, et al.
Publicado: (2022)

Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials
por: Citera, Gustavo, et al.
Publicado: (2021)

Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
por: Hirose, Wataru, et al.
Publicado: (2022)

Phase 1 Dose‐Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers
por: Miyoshi, So, et al.
Publicado: (2019)

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2016)

Precautions before starting tofacitinib in persons with rheumatoid arthritis
por: Swarnakar, Raktim, et al.
Publicado: (2022)

Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis
por: Mortezavi, Mahta, et al.
Publicado: (2023)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
por: Dougados, Maxime, et al.
Publicado: (2022)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
por: Burmester, Gerd R., et al.
Publicado: (2023)

Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme
por: Yamanaka, Hisashi, et al.
Publicado: (2017)

Comments on the article “Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study”
por: Thai, Thuy Nhu, et al.
Publicado: (2018)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2021)

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
por: Fleischmann, Roy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ntromifhfntfa0350qr2rinl12